- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06448637
SFERA A RILASCIO DI FARMACO vs STENT FARMACOATTIVO IN GRANDI VASI: ANALISI MORFOLOGICA E FUNZIONE VASOMOTORIA (STUDIO DEBORA) IN GRANDI VASI: ANALISI MORFOLOGICA E FUNZIONE VASOMOTORIA (STUDIO DEBORA)
SFERA A RILASCIO DI FARMACO vs STENT FARMACOATTIVO IN GRANDI VASI: ANALISI MORFOLOGICA E FUNZIONE VASOMOTORIA (STUDIO DEBORA)
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: FUNDACION EPIC
- Numero di telefono: 0034987876135
- Email: iepic@fundacionepic.org
Backup dei contatti dello studio
- Nome: IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
- Numero di telefono: 0034630901145
- Email: inigo.lozano@fundacionepic.org
Luoghi di studio
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall d'Hebron
-
Gijón, Spagna, 33394
- Reclutamento
- Hospital Universitario de Cabueñes
-
Huelva, Spagna, 21005
- Reclutamento
- Hospital Universitario Juan Ramón Jiménez
-
León, Spagna, 24008
- Reclutamento
- Hospital Universitario de Leon
-
Lugo, Spagna, 270003
- Reclutamento
- Hospital Universitario Lucus Augusti
-
Mérida, Spagna, 06800
- Reclutamento
- Hospital de Merida
-
Oviedo, Spagna, 33011
- Reclutamento
- Hospital Universitario Central de Asturias
-
Pontevedra, Spagna, 36071
- Reclutamento
- Hospital Provincial de Pontevedra
-
Tarragona, Spagna, 43005
- Reclutamento
- Hospital Universitari de Tarragona Joan XXIII
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Patients who meet all of the following conditions are included.
- Patients aged ≥ 18 years and;
- Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
- Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
- Patients who have been informed of the characteristics of the study and have provided their written informed consent.
Exclusion Criteria:
Patients who meet at least one of the following conditions are excluded:
- Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
- Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
- Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
- Patients who received a combination of DES and DCB in the same vessel
- Patients with glomerular filtration rate <30 ml/min/ 1.73 m2
- Patients with body mass index >35 (may affect the evaluation qualitative diameter of the coronary artery).
- Patients with symptomatic congestive heart failure.
- Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
- Patients with heart transplant.
- Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).
- Patients, women of childbearing age with a positive pregnancy test.
- Pregnant female patients.
- Patients included in other clinical trials with active follow-up.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Drug Coated Balloon (DCB)
Drug Coated Balloon (DCB) |
Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI) |
|
Sperimentale: Drug Eluting Stent (DES)
Drug Eluting Stent (DES) |
Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L).
Lasso di tempo: 8 months
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L). |
8 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Comparison of percentage of angiographic restenosis by quantitative coronary
Lasso di tempo: 8 months
|
Comparison of percentage of angiographic restenosis by quantitative coronary |
8 months
|
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography
Lasso di tempo: 8 months
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography |
8 months
|
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography
Lasso di tempo: 8 months
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography |
8 months
|
|
Percentage of of strut coverage by OCT(Optical Coherence Tomography) in the DES group
Lasso di tempo: 8 months
|
Percentage of of strut coverage by OCT in the DES group |
8 months
|
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months
Lasso di tempo: 8 months
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months |
8 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046.
- Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, King SB 3rd, Chronos N, Hou D. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. 2011 Feb;4(2):247-55. doi: 10.1016/j.jcin.2010.08.028.
- Gutierrez E G-LJ, Escaned J, Cruz I, Ojeda S, Romaguera R, Moreno R. Valoración de la función endotelial y provocación de vasoespasmo coronario mediante infusión intracoronaria de acetilcolina. Documento técnico de la ACI-SEC. REC Interv Cardiol. 2021;3(4):286-296.
- Gomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, Roura G, Rivero F, Fuentes L, Alfonso F, Otaegui I, Vandeloo B, Vaquerizo B, Sabate M, Comin-Colet J, Gomez-Hospital JA. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123. doi: 10.1161/JAHA.121.022123. Epub 2021 Nov 3.
- Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012 Jun;33(11):1325-33. doi: 10.1093/eurheartj/ehr466. Epub 2012 Apr 16.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EPIC37-DEBORA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .